An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg)
administered under supportive conditions to adult participants with severe TRD, in improving
depressive symptoms.